Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060122 · ClinicalTrials.gov registry record · NA
Combining CES Alpha-Stim and InterX for Optimized Rehabilitation Following Extremity Immobilization
A NA study, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT03060122: Completed NA study, sponsored by Brooke Army Medical Center.
NCT03060122 is a NA study that has completed, run by Brooke Army Medical Center. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060122, a NA study, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will be aimed at assessing the feasibility of a dual-device treatment prior to a rehabilitation session for an orthopaedic injury requiring immobilization, and its impact on improving outcomes and decreasing the risk for development of neuropathic pain. The investigators will evaluate the clinical feasibility and effectiveness of incorporating the Alpha-Stim and Inter-X treatment into a standard rehabilitation protocol to address risk factors associated with the development of neuropathic pain (i.e., pain, range of motion, and skin temperature) as well as its impact on reduced pain medication.
Primary Outcome
An 11-point verbalize NRS will be used to assess the subject's upper or lower extremity pain the day of each assessment as well as during therapy sessions. The 0 to 10 NPS has been found to be valid and reliable in many patient populations including the musculoskeletal population\[37\] and has been recommended for inclusion in the core NIH Toolbox for use with adults\[38\].
Interventions
- DEVICE Sham CES
- DEVICE NIN
- DEVICE CES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2019-08-07 |
| Phase | NA |
What the finished NCT03060122 record still lists
NCT03060122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Sham CES is the first listed.
NCT03060122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03060122 about?
NCT03060122 is a clinical study titled "Combining CES Alpha-Stim and InterX for Optimized Rehabilitation Following Extremity Immobilization". This study will be aimed at assessing the feasibility of a dual-device treatment prior to a rehabilitation session for an orthopaedic injury requiring immobilization, and its impact on improving outcomes and decreasing the risk for development of neuropathic pain. The investigators will evaluate the...
What is the current status of trial NCT03060122?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2018-03-01. Estimated completion is 2019-08-07.
What interventions are being tested in trial NCT03060122?
The interventions under investigation include: Sham CES (DEVICE), NIN (DEVICE), CES (DEVICE).
Who is sponsoring clinical trial NCT03060122?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03060122's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI